StockNews.AI
PHAT
StockNews.AI
118 days

Phathom Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide Business Update on Thursday, May 1, 2025

1. Phathom to host a conference call on May 1, 2025. 2. The call will cover Q1 2025 financial results and business updates. 3. Phathom focuses on treatments for gastrointestinal diseases. 4. Vonoprazan, their key product, is a first-in-class PCAB. 5. The recording will be available for 90 days post-call.

Earnings
+1.14%Current Return
VS
+3.44%S&P 500
$3.9604/23 08:08 AM EDTEvent Start
$4.00504/24 03:05 PM EDTLatest Updated
4m saved
Insight
Article

FAQ

Why Neutral?

The upcoming conference call will provide financial updates but no new product announcements are expected. Historically, earnings calls can lead to price stability as they reflect ongoing business performance.

How important is it?

The conference call is significant as earnings can directly affect stock price and investor sentiment. However, without major new developments, the overall impact may be limited.

Why Short Term?

The impact is immediate due to the nature of earnings announcements, which typically influence investor sentiment quickly.

Related Companies

AMGNABBVJNJ
• Management to host conference call on Thursday, May 1, 2025, at 8:00 am EDT FLORHAM PARK, N.J., April 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:00 am EDT on Thursday, May 1, 2025, to report its first quarter 2025 financial results and provide a business update. A live webcast and additional information about the presentation can be accessed on the Events & Presentations section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. A recording will be available for 90 days following the conclusion of the meeting. About Phathom Pharmaceuticals, Inc. Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) that is currently marketed in the United States as VOQUEZNA® (vonoprazan) tablets for the relief of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, in addition to VOQUEZNA® TRIPLE PAK® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA® DUAL PAK® (vonoprazan tablets, amoxicillin capsules) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the company’s website at www.phathompharma.com and follow on LinkedIn and X. MEDIA CONTACTNick Benedetto1-877-742-8466media@phathompharma.com INVESTOR CONTACTEric Sciorilli1-877-742-8466ir@phathompharma.com © 2025 Phathom Pharmaceuticals. All rights reserved. VOQUEZNA, VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.

Related News